Pharmather Holdings Ltd. (PHRRF)

[notorious_johnny_v]

PharmaTher - BUY rating and $5 PRICE TARGET

H.C. Wainwright analyst Patrick Trucchio initiated coverage of PharmaTher with a Buy rating and C$5 price target. PharmaTher's product pipeline targets the use of ketamine to treat Parkinson's disease, depression and amyotrophic lateral sclerosis, Trucchio tells investors in a research note. In the second half of 2021, potential positive events include data updates on Phase 2 programs including ketamine in Parkinson's disease, and KETABET, a combination of ketamine and betaine, in treatment-resistant depression, says the analyst.